Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Orphan Designations For Pediatric Subgroups Of Common Diseases To End

Dec 19 2017

• By Derrick Gingery

FDAEntrance_1200x675

Related Content

US FDA Outlines Streamlined Development Path For Targeted Therapies

Dec 16 2017

Pediatric Cancer Study Requirements Added To FDA User Fee Bill

Jul 12 2017

Orphan Pediatric Loophole To Be Closed By US FDA

Sep 13 2017

Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes

Oct 17 2017

ICH Expansion To Bring New Challenges For Global Consensus On Pediatric Extrapolation

Oct 24 2017

Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'

Dec 19 2017

PDUFA VI: Pediatrics Group Seeks Earlier And Faster Studies

Mar 17 2017

Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate

Mar 08 2017

Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says

Nov 28 2016

Additional Topics

United States FDA Rare Diseases Regulation Review Pathway BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.